BNP for Clinical Monitoring of Heart Failure

Heart Failure Clinics

Volumn 2, Issue 3, 2006, Pages 333-343

  Troughton, Richard W ^a   Richards, A Mark ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; METOPROLOL; N TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; NATRIURETIC FACTOR; NITRIC ACID DERIVATIVE; SPIRONOLACTONE; UNCLASSIFIED DRUG; VASODILATOR AGENT;

CLINICAL TRIAL; DISEASE MARKER; DISEASE SEVERITY; DRUG EFFICACY; DRUG MONITORING; DRUG POTENCY; DRUG RESPONSE; DRUG TARGETING; HEART DISEASE; HEART FAILURE; HIGH RISK PATIENT; HUMAN; PATIENT MONITORING; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; REVIEW; BLOOD; CONGESTIVE HEART FAILURE; MONITORING; PREDICTION AND FORECASTING;

HEART FAILURE, CONGESTIVE; HUMANS; MONITORING, PHYSIOLOGIC; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS;

EID: 33750814097     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2006.08.006     Document Type: Review

References (90)

1. Hunt S.A. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 46 6 (2005) e1-e82
2. Nicholls M.G., Lainchbury J.G., Richards A.M., et al. Brain natriuretic peptide-guided therapy for heart failure. Ann Med 33 6 (2001) 422-427
3. Swedberg K., Cleland J., Dargie H., et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 26 11 (2005) 1115-1140
4. Taylor A.L., Ziesche S., Yancy C., et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 351 20 (2004) 2049-2057
5. Tang W.H., and Francis G.S. The difficult task of evaluating how to monitor patients with heart failure. J Card Fail 11 6 (2005) 422-424
6. Hlatky M.A. Underuse of evidence-based therapies. Circulation 110 6 (2004) 644-645
7. Stafford R.S., and Radley D.C. The underutilization of cardiac medications of proven benefit, 1990 to 2002. J Am Coll Cardiol 41 1 (2003) 56-61
8. van Kraaij D.J., Jansen R.W., Bouwels L.H., et al. Furosemide withdrawal improves postprandial hypotension in elderly patients with heart failure and preserved left ventricular systolic function. Arch Intern Med 159 14 (1999) 1599-1605
9. Nohria A., Mielniczuk L.M., and Stevenson L.W. Evaluation and monitoring of patients with acute heart failure syndromes. Am J Cardiol 96 6A (2005) 32G-40G
10. Drazner M.H., Rame J.E., Stevenson L.W., et al. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. N Engl J Med 345 8 (2001) 574-581
11. Stevenson L.W., and Perloff J.K. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA 261 6 (1989) 884-888
12. Mo V.Y., and De Lemos J.A. Individualizing therapy in acute coronary syndromes: using a multiple biomarker approach for diagnosis, risk stratification, and guidance of therapy. Curr Cardiol Rep 6 4 (2004) 273-278
13. Anand I.S., Fisher L.D., Chiang Y.T., et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107 9 (2003) 1278-1283
14. Bettencourt P., Azevedo A., Pimenta J., et al. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 110 15 (2004) 2168-2174
15. Lainchbury J.G., Campbell E., Frampton C.M., et al. Brain natriuretic peptide and N-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol 42 4 (2003) 728-735
16. Logeart D., Thabut G., Jourdain P., et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol 43 4 (2004) 635-641
17. Maeda K., Tsutamoto T., Wada A., et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 36 5 (2000) 1587-1593
18. O'Brien R.J., Squire I.B., Demme B., et al. Pre-discharge, but not admission, levels of NT-proBNP predict adverse prognosis following acute LVF. Eur J Heart Fail 5 4 (2003) 499-506
19. Maisel A.S., Krishnaswamy P., Nowak R.M., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347 3 (2002) 161-167
20. Yasue H., Yoshimura M., Sumida H., et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 90 1 (1994) 195-203
21. Sumida H., Yasue H., Yoshimura M., et al. Comparison of secretion pattern between A-type and B-type natriuretic peptides in patients with old myocardial infarction. J Am Coll Cardiol 25 5 (1995) 1105-1110
22. Mukoyama M., Nakao K., Hosoda K., et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 87 4 (1991) 1402-1412
23. Iwanaga Y., Nishi I., Furuichi S., et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J Am Coll Cardiol 47 4 (2006) 742-748
24. Troughton R.W., Prior D.L., Pereira J.J., et al. Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function. J Am Coll Cardiol 43 3 (2004) 416-422
25. Mariano-Goulart D., Eberle M.C., Boudousq V., et al. Major increase in brain natriuretic peptide indicates right ventricular systolic dysfunction in patients with heart failure. Eur J Heart Fail 5 4 (2003) 481-488
26. Hunt P.J., Yandle T.G., Nicholls M.G., et al. The amino-terminal portion of pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma. Biochem Biophys Res Commun 214 3 (1995) 1175-1183
27. Yoshimura M., Yasue H., Okumura K., et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 87 2 (1993) 464-469
28. Nishikimi T., Yoshihara F., Morimoto A., et al. Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension 28 1 (1996) 22-30
29. Lee S.C., Stevens T.L., Sandberg S.M., et al. The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure. J Card Fail 8 3 (2002) 149-154
30. Tang W.H., Girod J.P., Lee M.J., et al. Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure. Circulation 108 24 (2003) 2964-2966
31. Tsutamoto T., Wada A., Sakai H., et al. Relationship between renal function and plasma brain natriuretic peptide in patients with heart failure. J Am Coll Cardiol 47 3 (2006) 582-586
32. Redfield M.M., Rodeheffer R.J., Jacobsen S.J., et al. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 40 5 (2002) 976-982
33. Wang T.J., Larson M.G., Levy D., et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 109 5 (2004) 594-600
34. McCullough P.A., Duc P., Omland T., et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 41 3 (2003) 571-579
35. Luchner A., Hengstenberg C., Lowel H., et al. Effect of compensated renal dysfunction on approved heart failure markers: direct comparison of brain natriuretic peptide (BNP) and N-terminal pro-BNP. Hypertension 46 1 (2005) 118-123
36. Knudsen C.W., Omland T., Clopton P., et al. Impact of atrial fibrillation on the diagnostic performance of B-type natriuretic peptide concentration in dyspneic patients: an analysis from the breathing not properly multinational study. J Am Coll Cardiol 46 5 (2005) 838-844
37. Wang T.J., Larson M.G., Levy D., et al. Heritability and genetic linkage of plasma natriuretic peptide levels. Circulation 108 1 (2003) 13-16
38. Nishikimi T., and Matsuoka H. Routine measurement of natriuretic peptide to guide the diagnosis and management of chronic heart failure. Circulation 109 25 (2004) e325-e326
39. Maisel A.S., Clopton P., Krishnaswamy P., et al. Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the Breathing Not Properly (BNP) multinational study. Am Heart J 147 6 (2004) 1078-1084
40. Januzzi J.L., van Kimmenade R., Lainchbury J., et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J 27 3 (2006) 330-337
41. Richards A.M., Crozier I.G., Yandle T.G., et al. Brain natriuretic factor: regional plasma concentrations and correlations with haemodynamic state in cardiac disease. Br Heart J 69 5 (1993) 414-417
42. Kazanegra R., Cheng V., Garcia A., et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Card Fail 7 1 (2001) 21-29
43. Johnson W., Omland T., Hall C., et al. Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J Am Coll Cardiol 39 10 (2002) 1623-1629
44. Knebel F., Schimke I., Pliet K., et al. NT-ProBNP in acute heart failure: correlation with invasively measured hemodynamic parameters during recompensation. J Card Fail 11 5 Suppl (2005) S38-S41
45. Yoshimura M., Yasue H., Tanaka H., et al. Responses of plasma concentrations of A type natriuretic peptide and B type natriuretic peptide to alacepril, an angiotensin-converting enzyme inhibitor, in patients with congestive heart failure. Br Heart J 72 6 (1994) 528-533
46. O'Neill J.O., Bott-Silverman C.E., McRae III A.T., et al. B-type natriuretic peptide levels are not a surrogate marker for invasive hemodynamics during management of patients with severe heart failure. Am Heart J 149 2 (2005) 363-369
47. Stevenson L.W. Are hemodynamic goals viable in tailoring heart failure therapy? Hemodynamic goals are relevant. Circulation 113 7 (2006) 1020-1027 [discussion 1033]
48. Nohria A., Tsang S.W., Fang J.C., et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol 41 10 (2003) 1797-1804
49. Steinhaus D., Reynolds D.W., Gadler F., et al. Implant experience with an implantable hemodynamic monitor for the management of symptomatic heart failure. Pacing Clin Electrophysiol 28 8 (2005) 747-753
50. Ritzema-Carter J.L., Smyth D., Troughton R.W., et al. Images in cardiovascular medicine. Dynamic myocardial ischemia caused by circumflex artery stenosis detected by a new implantable left atrial pressure monitoring device. Circulation 113 15 (2006) e705-e706
51. Braunschweig F., Fahrleitner-Pammer A., Mangiavacchi M., et al. Correlation between serial measurements of N-terminal pro brain natriuretic peptide and ambulatory cardiac filling pressures in outpatients with chronic heart failure. Eur J Heart Fail (2006) 19:[Epub ahead of print]
52. Bruins S., Fokkema M.R., Romer J.W., et al. High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem 50 11 (2004) 2052-2058
53. Wu A.H., Smith A., Wieczorek S., et al. Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol 92 5 (2003) 628-631
54. Latini R., Masson S., Anand I., et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 25 4 (2004) 292-299
55. Latini R., Masson S., Wong M., et al. Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. Am J Med 119 1 (2006) 70. e23-30
56. Nagaya N., Goto Y., Nishikimi T., et al. Sustained elevation of plasma brain natriuretic peptide levels associated with progressive ventricular remodelling after acute myocardial infarction. Clin Sci (Lond) 96 2 (1999) 129-136
57. Troughton R.W., Frampton C.M., Yandle T.G., et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355 9210 (2000) 1126-1130
58. Apple F.S., Panteghini M., Ravkilde J., et al. Quality specifications for B-type natriuretic peptide assays. Clin Chem 51 3 (2005) 486-493
59. Clerico A., Zucchelli G.C., Pilo A., et al. Clinical relevance of biological variation of B-type natriuretic peptide. Clin Chem 51 5 (2005) 925-926
60. Davis M.E., Pemberton C.J., Yandle T.G., et al. Urocortin-1 infusion in normal humans. J Clin Endocrinol Metab 89 3 (2004) 1402-1409
61. Davis M.E., Richards A.M., Nicholls M.G., et al. Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure. Circulation 113 7 (2006) 977-985
62. Lainchbury J.G., Troughton R.W., Frampton C.M., et al. NTproBNP-guided drug treatment for chronic heart failure: design and methods in the "BATTLESCARRED" trial. Eur J Heart Fail 8 5 (2006) 532-538
63. Cheng V., Kazanagra R., Garcia A., et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 37 2 (2001) 386-391
64. Bettencourt P., Ferreira S., Azevedo A., et al. Preliminary data on the potential usefulness of B-type natriuretic peptide levels in predicting outcome after hospital discharge in patients with heart failure. Am J Med 113 3 (2002) 215-219
65. Mueller C., Scholer A., Laule-Kilian K., et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 350 7 (2004) 647-654
66. Davis M., Espiner E., Richards G., et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet 343 8895 (1994) 440-444
67. Bettencourt P., Frioes F., Azevedo A., et al. Prognostic information provided by serial measurements of brain natriuretic peptide in heart failure. Int J Cardiol 93 1 (2004) 45-48
68. Richards A.M., Troughton R., Lainchbury J., et al. Guiding and monitoring of heart failure therapy with NT-ProBNP: concepts and clinical studies. J Card Fail 11 5 Suppl (2005) S34-S37
69. Nishikimi T., and Matsuoka H. Plasma brain natriuretic peptide levels indicate the distance from decompensated heart failure. Circulation 109 25 (2004) e329-e330
70. Vantrimpont P., Rouleau J.L., Ciampi A., et al. Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study. Eur Heart J 19 10 (1998) 1552-1563
71. Sabatine M.S., Morrow D.A., de Lemos J.A., et al. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol 44 10 (2004) 1988-1995
72. Tsutamoto T., Wada A., Maeda K., et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 37 5 (2001) 1228-1233
73. Yan R.T., White M., Yan A.T., et al. Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both. Am J Cardiol 96 5 (2005) 698-704
74. Hartmann F., Packer M., Coats A.J., et al. NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy. Eur J Heart Fail 6 3 (2004) 343-350
75. Murdoch D.R., McDonagh T.A., Byrne J., et al. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J 138 6 Pt 1 (1999) 1126-1132
76. Richards A.M., Doughty R., Nicholls M.G., et al. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. Circulation 99 6 (1999) 786-792
77. Braunschweig F., Linde C., Eriksson M.J., et al. Continuous haemodynamic monitoring during withdrawal of diuretics in patients with congestive heart failure. Eur Heart J 23 1 (2002) 59-69
78. The Randomized Evaluation of Strategies for Left Ventricular Dysfunction Investigators. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: the randomized evaluation of strategies for left ventricular dysfunction pilot study. Circulation 101 4 (2000) 378-384
79. Stanek B., Frey B., Hulsmann M., et al. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 38 2 (2001) 436-442
80. Doughty R.N., Whalley G.A., Walsh H.A., et al. Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy. Circulation 109 2 (2004) 201-206
81. Sanderson J.E., Chan W.W., Hung Y.T., et al. Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third generation vasodilating beta blocker. Br Heart J 74 5 (1995) 502-507
82. Richards A.M., Doughty R., Nicholls M.G., et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J Am Coll Cardiol 37 7 (2001) 1781-1787
83. Hartmann F., Packer M., Coats A.J., et al. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation 110 13 (2004) 1780-1786
84. Jourdain P., Funck F., Gueffet P., et al. Benefits of BNP plasma levels for optimizing therapy: the systolic heart failure treatment supported by BNP multicenter randomized trial (STARS-BNP). J Am Coll Cardiol 45 Suppl A (2005) 3A
85. Shah M.R., Claise K.A., Bowers M.T., et al. Testing new targets of therapy in advanced heart failure: the design and rationale of the Strategies for Tailoring Advanced Heart Failure Regimens in the Outpatient Setting: BRain NatrIuretic Peptide Versus the Clinical CongesTion ScorE (STARBRITE) trial. Am Heart J 150 5 (2005) 893-898
86. Brunner-La Rocca H.P., Buser P.T., Schindler R., et al. Management of elderly patients with congestive heart failure-design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). Am Heart J 151 5 (2006) 949-955
87. Sinha A.M., Filzmaier K., Breithardt O.A., et al. Usefulness of brain natriuretic peptide release as a surrogate marker of the efficacy of long-term cardiac resynchronization therapy in patients with heart failure. Am J Cardiol 91 6 (2003) 755-758
88. Gerber I.L., Stewart R.A., Legget M.E., et al. Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation 107 14 (2003) 1884-1890
89. Sutton T.M., Stewart R.A., Gerber I.L., et al. Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation. J Am Coll Cardiol 41 12 (2003) 2280-2287
90. Weber M., Hausen M., Arnold R., et al. The prognostic value of N-terminal pro B-type natriuretic peptide (NT-proBNP) for conservatively and surgically treated patients with aortic valve stenosis. Heart (2006) [Epub ahead of print]